peripheral nerve disease; peripheral neuropathy

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]

Classification

Etiology

Epidemiology

Pathology

Clinical manifestations

Laboratory

* also see ARUP consult[20]

Diagnostic procedures

Radiology

Complications

Differential diagnosis

Management

* only duloxetine, pregabalin & tapendolol FDA-approved for treatment of painful peripheral neuropathy[3]

More general terms

More specific terms

Additional terms

References

  1. ↑ Harrison's Principles of Internal Medicine, 13th ed. Companion Handbook, Isselbacher et al (eds), McGraw-Hill Inc. NY, 1995, pg 829-39
  2. ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 1046-47
  3. ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 Medical Knowledge Self Assessment Program (MKSAP) 11, 15, 16, 17, 18, 19. American College of Physicians, Philadelphia 1998, 2009, 2012, 2015, 2018, 2021.
    Medical Knowledge Self Assessment Program (MKSAP) 19 Board Basics. An Enhancement to MKSAP19. American College of Physicians, Philadelphia 2022
  4. ↑ 4.0 4.1 Journal Watch 25(9):74, 2005 Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005 Mar 31;352(13):1324-34. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15800228
  5. ↑ 5.0 5.1 Journal Watch, Mass Med Soc 20(1):11 (Jan 1) 2000
  6. ↑ England JD et al Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Neurology 2009 Jan 13;72(2):185-92 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19056666
  7. ↑ England JD et al Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Neurology 2009 Jan 13;72(2):177-84 PMID: https://www.ncbi.nlm.nih.gov/pubmed/19056667
  8. ↑ 8.0 8.1 Simpson DM et al. Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial. Neurology 2010 Feb 2; 74:413. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20124207
  9. ↑ 9.0 9.1 ARUP Consult: Autoimmune Neuropathies - Neuropathic Disease deprecated reference
  10. ↑ 10.0 10.1 Smith EM et al Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy. A Randomized Clinical Trial. JAMA. 2013;309(13):1359-1367 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23549581 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1674238
  11. ↑ 11.0 11.1 Lauria G, Merkies IS, Faber CG. Small fibre neuropathy. Curr Opin Neurol. 2012 Oct;25(5):542-9 PMID: https://www.ncbi.nlm.nih.gov/pubmed/22941266
  12. ↑ Ward RE et al. Sensory and motor peripheral nerve function and incident mobility disability. J Am Geriatr Soc 2014 Dec; 62:2273 PMID: https://www.ncbi.nlm.nih.gov/pubmed/25482096
  13. ↑ Levine TD, Saperstein DS. Laboratory evaluation of peripheral neuropathy. Neurol Clin. 2013 May;31(2):363-76. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23642714
  14. ↑ 14.0 14.1 Nelson R Persistent Chemo-Induced Neuropathy Impacts Functioning. Medscape Oncology. Jan 14, 2016 http://www.medscape.com/viewarticle/857235
  15. ↑ Callaghan B, McCammon R, Kerber K, Xu X, Langa KM, Feldman E. Tests and expenditures in the initial evaluation of peripheral neuropathy. Arch Intern Med. 2012 Jan 23;172(2):127-32. PMID: https://www.ncbi.nlm.nih.gov/pubmed/22271119 Free PMC Article
  16. ↑ Callaghan BC, Burke JF, Rodgers A, Expenditures in the elderly with peripheral neuropathy: Where should we focus cost-control efforts? Neurol Clin Pract. 2013 Oct;3(5):421-430. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24175158 Free PMC Article
  17. ↑ 17.0 17.1 Hanewinckel R et al. Prevalence of polyneuropathy in the general middle-aged and elderly population. Neurology 2016 Nov 1; 87:1892 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27683845
  18. ↑ 18.0 18.1 Geriatric Review Syllabus, 10th edition (GRS10) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2019
  19. ↑ National Institute of Neurological Disorders and Stroke (NINDS)
    NINDS Peripheral Neuropathy Information Page https://www.ninds.nih.gov/Disorders/All-Disorders/Peripheral-Neuropathy-Information-Page
    Peripheral Neuropathy Fact Sheet https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Peripheral-Neuropathy-Fact-Sheet
  20. ↑ 20.0 20.1 ARUP Consult: Autoimmune Neuropathies - Neuropathic Disease The Physician's Guide to Laboratory Test Selection & Interpretation https://www.arupconsult.com/content/autoimmune-neuropathies
  21. ↑ 21.0 21.1 Barohn RJ, Gajewski B, Pasnoor M et al. Patient assisted intervention for neuropathy: Comparison of treatment in real life situations (PAIN-CONTRoLS): Bayesian adaptive comparative effectiveness randomized trial. JAMA Neurol 2020 Aug 17; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/32809014 https://jamanetwork.com/journals/jamaneurology/fullarticle/2769608
  22. ↑ 22.0 22.1 Hicks CW, Wang D, Matsushita K et al Peripheral Neuropathy and All-Cause and Cardiovascular Mortality in U.S. Adults. Ann Intern Med. 2020. Dec 8. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33284680 https://www.acpjournals.org/doi/10.7326/M20-1340
  23. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named ref23

Patient information

peripheral nerve disease (peripheral neuropathy) patient information

Retrieved from "https://aaushi.info/w/index.php?title=A21496&oldid=1203429"